Open Access

DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines

  • Authors:
    • Tassanee Lerksuthirat
    • Sunisa Prasopporn
    • Rakkreat Wikiniyadhanee
    • Sermsiri Chitphuk
    • Wasana Stitchantrakul
    • Paravee Owneium
    • Siwanon Jirawatnotai
    • Donniphat Dejsuphong
  • View Affiliations

  • Published online on: January 7, 2025     https://doi.org/10.3892/ol.2025.14874
  • Article Number: 128
  • Copyright: © Lerksuthirat et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cholangiocarcinoma (CCA) is a biliary tract carcinoma that is challenging to treat due to its heterogeneity and limited treatment options. Genetic alterations in DNA damage response (DDR) pathways and homologous recombination (HR) defects are common in CCA. This has prompted interest in the use of ataxia telangiectasia and Rad3‑related protein (ATR) and poly(ADP‑ribose) polymerase (PARP) inhibitors to treat CCA. The present study investigated the impact of an ATR inhibitor and various PARP inhibitors, individually and in combination, on CCA cell lines with different DDR mutation profiles. DDR gene alterations in these cell lines were analyzed, and the responses of the cells to treatment with the PARP inhibitors olaparib, veliparib and talazoparib and/or the ATR inhibitor AZD6738 were evaluated. Assessments focused on cellular viability, clonogenic survival and the combination index, alongside changes in DNA damage assessed via the formation of micronuclei and γ‑H2A histone family member X foci. The results revealed that the CCA cell lines with more DDR mutations exhibited greater sensitivity to single and combination treatments. Talazoparib was found to be the most potent PARP inhibitor in the CCA cell lines. The combination of AZD6738 and talazoparib demonstrated varying synergistic effects depending on the genetic background of the CCA cells, with greater efficacy in the cell lines less sensitive to single drug treatments. Mechanistically, this combination promoted the accumulation of DNA damage, including DNA double‑strand breaks. Overall, the study underscores the importance of HR in CCA. It reveals an association between the extent of DDR mutations and the response to AZD6738 and PARP inhibitors in CCA, both as single agents and in combination. These findings highlight that the number of mutated genes influences variability in the drug response.
View Figures
View References

Related Articles

Journal Cover

March-2025
Volume 29 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lerksuthirat T, Prasopporn S, Wikiniyadhanee R, Chitphuk S, Stitchantrakul W, Owneium P, Jirawatnotai S and Dejsuphong D: DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines. Oncol Lett 29: 128, 2025.
APA
Lerksuthirat, T., Prasopporn, S., Wikiniyadhanee, R., Chitphuk, S., Stitchantrakul, W., Owneium, P. ... Dejsuphong, D. (2025). DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines. Oncology Letters, 29, 128. https://doi.org/10.3892/ol.2025.14874
MLA
Lerksuthirat, T., Prasopporn, S., Wikiniyadhanee, R., Chitphuk, S., Stitchantrakul, W., Owneium, P., Jirawatnotai, S., Dejsuphong, D."DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines". Oncology Letters 29.3 (2025): 128.
Chicago
Lerksuthirat, T., Prasopporn, S., Wikiniyadhanee, R., Chitphuk, S., Stitchantrakul, W., Owneium, P., Jirawatnotai, S., Dejsuphong, D."DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines". Oncology Letters 29, no. 3 (2025): 128. https://doi.org/10.3892/ol.2025.14874